{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:11:32Z","timestamp":1767712292885,"version":"3.48.0"},"posted":{"date-parts":[[2026,1,6]]},"group-title":"In Review","reference-count":59,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG 077700"],"award-info":[{"award-number":["AG 077700"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,27]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [\n                  <sup>18<\/sup>\n                  F]MK-6240 has the potential in DSAD to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex (FCX) and temporal cortex (TCX) postmortem brain slices of DSAD (n\u2009=\u20095), AD (n\u2009=\u20095), and cognitively normal (CN) (n\u2009=\u20095) cases indicated similarly high [\n                  <sup>18<\/sup>\n                  F]MK-6240 binding in DSAD and AD cases. Anti-tau immunostains confirmed total tau presence so there was alignment in anti-tau abundance with quantification of [\n                  <sup>18<\/sup>\n                  F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)\/white matter (WM) ratios of 2.8 and 2.5 respectively. For drug effects on [\n                  <sup>18<\/sup>\n                  F]MK-6240 binding, self-displacement of [\n                  <sup>18<\/sup>\n                  F]MK-6240 was by 88% among DSAD cases and 85% among AD cases while IPPI displaced [\n                  <sup>18<\/sup>\n                  F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194, a specific phosphokinase inhibitor, minimally displaced [\n                  <sup>18<\/sup>\n                  F]MK-6240 binding. Harmine competed with [\n                  <sup>18<\/sup>\n                  F]MK-6240 with an IC\n                  <sub>50<\/sub>\n                  value of 290\u2009\u00b1\u2009218 nM and 92\u2009\u00b1\u200915 nM for DSAD and AD cases, respectively, suggesting unique tau binding. High meninges off-target (non-tau) binding of [\n                  <sup>18<\/sup>\n                  F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 \u00b5M) blocked 44% and T807 (10 \u00b5M) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethylenimine reduced 70% of [\n                  <sup>18<\/sup>\n                  F]MK-6240 binding. The tau imaging agent, [\n                  <sup>125<\/sup>\n                  I]IPPI, an analog of [\n                  <sup>18<\/sup>\n                  F]MK-6240, exhibited minimal binding to CN meninges. Our findings suggest [\n                  <sup>18<\/sup>\n                  F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to be a weak tau drug, and off-target nonspecific meninges binding maybe due to the primary aromatic amine group in [\n                  <sup>18<\/sup>\n                  F]MK-6240.\n                <\/p>","DOI":"10.21203\/rs.3.rs-8463304\/v1","type":"posted-content","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:06:31Z","timestamp":1767711991000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer\u2019s disease and assessment of off-target (non-tau) binding"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3104-9523","authenticated-orcid":false,"given":"Fariha","family":"Karim","sequence":"first","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0267-2299","authenticated-orcid":false,"given":"Agnes P.","family":"Biju","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-294X","authenticated-orcid":false,"given":"Christopher","family":"Liang","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camryn J.","family":"Santos","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maharishi","family":"Rajarethenam","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-877X","authenticated-orcid":false,"given":"Jogeshwar","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"University of California Irvine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2788.2010.01271.x","article-title":"The relationship between acquired impairments of executive function and behaviour change in adults with Down syndrome","volume":"54","author":"Adams D","year":"2010","unstructured":"Adams D, Oliver C (2010) The relationship between acquired impairments of executive function and behaviour change in adults with Down syndrome. J Intellect Disabil Res 54(5):393\u2013405. https:\/\/doi.org\/10.1111\/j.1365-2788.2010.01271.x","journal-title":"J Intellect Disabil Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-019-0686-6","article-title":"Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue","volume":"7","author":"Aguero C","year":"2019","unstructured":"Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, Marquie M, Johnson KA, El Fakhri G, Frosch MP, Gomez-Isla T (2019) Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun 7:37. https:\/\/doi.org\/10.1186\/s40478-019-0686-6","journal-title":"Acta Neuropathol Commun"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-023-02672-z","article-title":"Head-to-head comparison of [(18)F]-Flortaucipir, [(18)F]-MK-6240 and [(18)F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases","volume":"147","author":"Aguero C","year":"2024","unstructured":"Aguero C, Dhaynaut M, Amaral AC, Moon SH, Neelamegam R, Scapellato M, Carazo-Casas C, Kumar S, El Fakhri G, Johnson K, Frosch MP (2024) Head-to-head comparison of [(18)F]-Flortaucipir, [(18)F]-MK-6240 and [(18)F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases. Acta Neuropathol 147:25. https:\/\/doi.org\/10.1007\/s00401-023-02672-z","journal-title":"Acta Neuropathol"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2967\/jnumed.118.209650","article-title":"In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls","volume":"60","author":"Betthauser TJ","year":"2019","unstructured":"Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, Stone CK, Rowley HA, Johnson SC, Christian BT (2019) In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med 60(1):93\u201399. https:\/\/doi.org\/10.2967\/jnumed.118.209650","journal-title":"J Nucl Med"},{"key":"ref5","volume-title":"Measurement of tau protein and A\u03b2 amyloid plaques in postmortem human brains of Down syndrome and Alzheimer\u2019s disease by using [125I]IPPI and [125I]IBETA autoradiography","author":"Biju AP","year":"2025","unstructured":"Biju AP et al (2025) Measurement of tau protein and A\u03b2 amyloid plaques in postmortem human brains of Down syndrome and Alzheimer\u2019s disease by using [125I]IPPI and [125I]IBETA autoradiography. Brain Disorders. Under review"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"110777","DOI":"10.1016\/j.brainresbull.2023.110777","article-title":"Tau trajectory in Alzheimer\u2019s disease: Evidence from the connectome-based computational models","volume":"203","author":"Bitra VR","year":"2023","unstructured":"Bitra VR, Challa SR, Adiukwu PC, Rapaka D (2023) Tau trajectory in Alzheimer\u2019s disease: Evidence from the connectome-based computational models. Brain Res Bull 203:110777. https:\/\/doi.org\/10.1016\/j.brainresbull.2023.110777","journal-title":"Brain Res Bull"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak H","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259. https:\/\/doi.org\/10.1007\/BF00308809","journal-title":"Acta Neuropathol"},{"issue":"338","key":"ref8","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier MR","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, Owen C, Aldea P, Su Y, Hassenstab J, Cairns NJ (2016) Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med 8(338):338ra66. https:\/\/doi.org\/10.1126\/scitranslmed.aaf2362","journal-title":"Sci Transl Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(83)90427-x","author":"Bruns RF","year":"1983","unstructured":"Bruns RF, Lawson-Wendling K, Pugsley TA (1983) A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. Analytical biochemistry. Jul 1;132(1):74\u201381. https:\/\/doi.org\/10.1016\/0003-2697(83)90427-x"},{"issue":"2","key":"ref10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1042\/BJ20140772","article-title":"Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain","volume":"463","author":"Butterfield DA","year":"2014","unstructured":"Butterfield DA, Di Domenico F, Swomley AM, Head E, Perluigi M (2014) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 463(2):177\u2013189. https:\/\/doi.org\/10.1042\/BJ20140772","journal-title":"Biochem J"},{"issue":"5 Pt 1","key":"ref11","doi-asserted-by":"publisher","first-page":"L421","DOI":"10.1152\/ajplung.1993.265.5.L421","article-title":"Radioligand binding methods: practical guide and tips","volume":"265","author":"Bylund DB","year":"1993","unstructured":"Bylund DB, Toews ML (1993) Radioligand binding methods: practical guide and tips. Am J Physiol 265(5 Pt 1):L421\u2013L429. https:\/\/doi.org\/10.1152\/ajplung.1993.265.5.L421","journal-title":"Am J Physiol"},{"issue":"7","key":"ref12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1021\/acschemneuro.6b00051","article-title":"Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain","volume":"7","author":"Cai L","year":"2016","unstructured":"Cai L, Qu B, Hurtle BT, Dadiboyena S, Diaz-Arrastia R, Pike VW (2016) Candidate PET Radioligand Development for Neurofibrillary Tangles: Two Distinct Radioligand Binding Sites Identified in Postmortem Alzheimer's Disease Brain. ACS Chem Neurosci 7(7):897\u2013911. https:\/\/doi.org\/10.1021\/acschemneuro.6b00051","journal-title":"ACS Chem Neurosci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien DT","year":"2013","unstructured":"Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457\u2013468. https:\/\/doi.org\/10.3233\/JAD-122059","journal-title":"J Alzheimers Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"152166","DOI":"10.1016\/j.bbrc.2025.152166","article-title":"Structure-guided discovery of tau-phosphorylating kinase DYRK1A inhibitors for therapeutic targeting of neuroinflammatory diseases: Insights from microsecond MD simulation and MMPBSA analyses. Biochemical and Biophysical Research Communications","author":"Choudhury A","year":"2025","unstructured":"Choudhury A, Khan S, Saeed MU, Mohammad T, Hussain A, AlAjmi MF, Fatima U, Islam A, Hassan MI (2025) Structure-guided discovery of tau-phosphorylating kinase DYRK1A inhibitors for therapeutic targeting of neuroinflammatory diseases: Insights from microsecond MD simulation and MMPBSA analyses. Biochemical and Biophysical Research Communications. 152166. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152166"},{"issue":"5","key":"ref15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/jlcr.3496","article-title":"cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles","volume":"60","author":"Collier TL","year":"2017","unstructured":"Collier TL, Yokell DL, Livni E et al (2017) cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles. J Label Comp Radiopharm 60(5):263\u2013269. https:\/\/doi.org\/10.1002\/jlcr.3496","journal-title":"J Label Comp Radiopharm"},{"issue":"7717","key":"ref16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41586-018-0368-8","article-title":"Functional aspects of meningeal lymphatics in ageing and Alzheimer\u2019s disease","volume":"560","author":"Mesquita S","year":"2018","unstructured":"Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, Onengut-Gumuscu S, Farber E, Raper D, Viar KE (2018) Functional aspects of meningeal lymphatics in ageing and Alzheimer\u2019s disease. Nature 560(7717):185\u2013191","journal-title":"Nature"},{"issue":"1","key":"ref17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13024-017-0229-1","article-title":"A validated antibody panel for the characterization of tau post-translational modifications","volume":"12","author":"Ercan E","year":"2017","unstructured":"Ercan E, Eid S, Weber C, Kowalski A, Bichmann M, Behrendt A, Matthes F, Krauss S, Reinhardt P, Fulle S, Ehrnhoefer DE (2017) A validated antibody panel for the characterization of tau post-translational modifications. Mol neurodegeneration 12(1):87. https:\/\/doi.org\/10.1186\/s13024-017-0229-1","journal-title":"Mol neurodegeneration"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/brainsci8100187","article-title":"DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome","volume":"8","author":"Feki A","year":"2018","unstructured":"Feki A, Hibaoui Y (2018) DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome. Brain Sci 8(10):187","journal-title":"Brain Sci"},{"issue":"3\u20134","key":"ref19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000442941","article-title":"Frontal lobe degeneration in adults with Down syndrome and Alzheimer's disease: a review","volume":"41","author":"Fonseca LM","year":"2016","unstructured":"Fonseca LM, Yokomizo JE, Bottino CM, Fuentes D (2016) Frontal lobe degeneration in adults with Down syndrome and Alzheimer's disease: a review. Dement Geriatr Cogn Disord 41(3\u20134):123\u2013136. https:\/\/doi.org\/10.1159\/000442941","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2967\/jnumed.120.254961","article-title":"Direct comparison of the tau PET tracers 18F-flortaucipir and 18F-MK-6240 in human cases","volume":"63","author":"Gogola A","year":"2022","unstructured":"Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, Laymon CM, Mason NS, Ikonomovic MD, Mathis CA, Snitz BE (2022) Direct comparison of the tau PET tracers 18F-flortaucipir and 18F-MK-6240 in human cases. J Nucl Med 63(1):108\u2013116. https:\/\/doi.org\/10.2967\/jnumed.120.254961","journal-title":"J Nucl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1046\/j.1471-4159.1995.65020732.x","article-title":"Phosphatase Activity Toward Abnormally Phosphorylated \u03c4: Decrease in Alzheimer Disease Brain","volume":"65","author":"Gong CX","year":"1995","unstructured":"Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Phosphatase Activity Toward Abnormally Phosphorylated \u03c4: Decrease in Alzheimer Disease Brain. J Neurochem 65:732\u2013738. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.65020732.x","journal-title":"J Neurochem"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e057426","DOI":"10.1002\/alz.057426","article-title":"Longitudinal investigation for enhancing Down Syndrome Research (LIFE\u2010DSR) Study: Tau PET and CSF sub\u2010studies","volume":"17","author":"Hendrix JA","year":"2021","unstructured":"Hendrix JA, Britton A, Christian BT, Ledesma DL, Egan MF, Feldman H, Hendrix SB, Herring WJ, Kennedy ME, Nicodemus-Johnson J, Revta C (2021) Longitudinal investigation for enhancing Down Syndrome Research (LIFE\u2010DSR) Study: Tau PET and CSF sub\u2010studies. Alzheimer's Dement 17:e057426. https:\/\/doi.org\/10.1002\/alz.057426","journal-title":"Alzheimer's Dement"},{"issue":"4","key":"ref23","doi-asserted-by":"publisher","first-page":"e70024","DOI":"10.1002\/syn.70024","article-title":"[125I] IPPI for Tau Imaging: Binding Studies in Postmortem Human Alzheimer's Disease Hippocampus-Subiculum and Evaluation of Drug Effects","volume":"79","author":"Karim F","year":"2025","unstructured":"Karim F, Delaney BA, Mondal R, Liang C, Serrano GE, Beach TG, Mukherjee J (2025) [125I] IPPI for Tau Imaging: Binding Studies in Postmortem Human Alzheimer's Disease Hippocampus-Subiculum and Evaluation of Drug Effects. Synapse 79(4):e70024. https:\/\/doi.org\/10.1002\/syn.70024","journal-title":"Synapse"},{"issue":"3","key":"ref24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0169-409x(01)00202-2","article-title":"Design and gene delivery activity of modified polyethylenimines","volume":"53","author":"Kircheis R","year":"2001","unstructured":"Kircheis R, Wightman L, Wagner E (2001) Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 53(3):341\u2013358. https:\/\/doi.org\/10.1016\/s0169-409x(01)00202-2","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"ref25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ana.24271","article-title":"Impairment of paravascular clearance pathways in the aging brain","volume":"76","author":"Kress BT","year":"2014","unstructured":"Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, Liew JA, Plog BA (2014) Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 76(6):845\u2013861. https:\/\/doi.org\/10.1002\/ana.24271","journal-title":"Ann Neurol"},{"issue":"5","key":"ref26","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.bmc.2014.01.016","article-title":"Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT\u2087 receptor","volume":"22","author":"Lacivita E","year":"2014","unstructured":"Lacivita E, Niso M, Hansen HD, Di Pilato P, Herth MM, Lehel S, Ettrup A, Montenegro L, Perrone R, Berardi F, Colabufo NA, Leopoldo M, Knudsen GM (2014) Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT\u2087 receptor. Bioorg Med Chem 22(5):1736\u20131750. https:\/\/doi.org\/10.1016\/j.bmc.2014.01.016","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"ref27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13024-020-00414-3","article-title":"Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue","volume":"15","author":"Lemoine L","year":"2020","unstructured":"Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, Lott I, Carroll S, Bharani K, Thomas S, Gilmore A (2020) Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue. Mol neurodegeneration 15(1):68. https:\/\/doi.org\/10.1186\/s13024-020-00414-3","journal-title":"Mol neurodegeneration"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/brain\/awab392","article-title":"18F-MK-6240 tau-PET in genetic frontotemporal dementia","volume":"145","author":"Levy JP","year":"2022","unstructured":"Levy JP, Bezgin G, Savard M, Pascoal TA, Finger E, Laforce R Jr, Sonnen JA, Soucy JP, Gauthier S, Rosa-Neto P, Ducharme S (2022) 18F-MK-6240 tau-PET in genetic frontotemporal dementia. Brain 145(5):1763\u20131772. https:\/\/doi.org\/10.1093\/brain\/awab392","journal-title":"Brain"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sj.gt.3302135","article-title":"CNS gene transfer mediated by a novel controlled release system based on DNA complexes of degradable polycation PPE-EA: a comparison with polyethylenimine\/DNA complexes","volume":"11","author":"Li Y","year":"2004","unstructured":"Li Y, Wang J, Lee CG, Wang CY, Gao SJ, Tang GP, Ma YX, Yu H, Ma HQ, Leong KW, Wang S (2004) CNS gene transfer mediated by a novel controlled release system based on DNA complexes of degradable polycation PPE-EA: a comparison with polyethylenimine\/DNA complexes. Gene Ther 11(1):109\u2013114. https:\/\/doi.org\/10.1038\/sj.gt.3302135","journal-title":"Gene Ther"},{"issue":"3","key":"ref30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3233\/JAD-2008-13307","article-title":"Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome","volume":"13","author":"Liang Z","year":"2008","unstructured":"Liang Z, Liu F, Iqbal K, Grundke-Iqbal I, Wegiel J, Gong CX (2008) Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimer\u2019s Disease 13(3):295\u2013302. https:\/\/doi.org\/10.3233\/JAD-2008-13307","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"15","key":"ref31","doi-asserted-by":"publisher","first-page":"5769","DOI":"10.3390\/molecules28155769","article-title":"[125I]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer's Disease Brain","volume":"28","author":"Limpengco RR","year":"2023","unstructured":"Limpengco RR, Liang C, Sandhu YK, Mukherjee J (2023) [125I]INFT: Synthesis and Evaluation of a New Imaging Agent for Tau Protein in Post-Mortem Human Alzheimer's Disease Brain. Molecules 28(15):5769. https:\/\/doi.org\/10.3390\/molecules28155769","journal-title":"Molecules"},{"issue":"9","key":"ref32","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1096\/fj.07-104539","article-title":"Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome","volume":"22","author":"Liu F","year":"2008","unstructured":"Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, Ramakrishna N, Gong CX (2008) Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 22(9):3224. https:\/\/doi.org\/10.1096\/fj.07-104539","journal-title":"FASEB J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1162\/imag_a_00402","article-title":"Test\u2013retest performance of [18F] MK-6240 tau burden and relative delivery indices in cognitively normal older cases using PET\/MRI","volume":"2","author":"Lois C","year":"2024","unstructured":"Lois C, Fu JF, Salvatore AN, Garimella AH, Huell D, Sari H, Garcia DI, Mercaldo ND, Dickerson B, Johnson KA, Catana C (2024) Test\u2013retest performance of [18F] MK-6240 tau burden and relative delivery indices in cognitively normal older cases using PET\/MRI. Imaging Neurosci 2:1\u201320","journal-title":"Imaging Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui\u00e9 M","year":"2015","unstructured":"Marqui\u00e9 M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787\u2013800. https:\/\/doi.org\/10.1002\/ana.24517","journal-title":"Ann Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00401-017-1740-8","article-title":"[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging","volume":"134","author":"Marqui\u00e9 M","year":"2017","unstructured":"Marqui\u00e9 M, Siao Tick Chong M, Ant\u00f3n-Fern\u00e1ndez A, Verwer EE, S\u00e1ez-Calveras N, Meltzer AC et al (2017) [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. Acta Neuropathol 134:619\u2013628. https:\/\/doi.org\/10.1007\/s00401-017-1740-8","journal-title":"Acta Neuropathol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-017-0482-0","article-title":"Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson\u2019s case","volume":"5","author":"Marqui\u00e9 M","year":"2017","unstructured":"Marqui\u00e9 M, Verwer EE, Meltzer AC, Kim SJW, Ag\u00fcero C, Gonzalez J et al (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson\u2019s case. Acta Neuropathol Commun 5:75. https:\/\/doi.org\/10.1186\/s40478-017-0482-0","journal-title":"Acta Neuropathol Commun"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40478-015-0240-0","article-title":"Cortical tau load is associated with white matter hyperintensities","volume":"3","author":"McAleese KE","year":"2015","unstructured":"McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, Beverley JR, Taylor JP, Thomas AJ, O'Brien JT, Attems J (2015) Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol Commun 3:60. https:\/\/doi.org\/10.1186\/s40478-015-0240-0","journal-title":"Acta Neuropathol Commun"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1162\/imag_a_00135","article-title":"Evaluating the effect of extra-cerebral off-target binding in [F-18] MK6240 PET scans in early-stage Alzheimer\u2019s disease","volume":"2","author":"McVea A","year":"2024","unstructured":"McVea A, DiFilippo A, McLachlan MJ, Zammit MD, Bendlin B, Johnson SC, Betthauser TJ, Christian BT (2024) Evaluating the effect of extra-cerebral off-target binding in [F-18] MK6240 PET scans in early-stage Alzheimer\u2019s disease. Imaging Neurosci 2:1\u201320. https:\/\/doi.org\/10.1162\/imag_a_00135","journal-title":"Imaging Neurosci"},{"issue":"1","key":"ref39","doi-asserted-by":"publisher","first-page":"e22183","DOI":"10.1002\/syn.22183","article-title":"Development and evaluation of [125I] IPPI for Tau imaging in postmortem human Alzheimer's disease brain","volume":"75","author":"Mukherjee J","year":"2021","unstructured":"Mukherjee J, Liang C, Patel KK, Lam PQ, Mondal R (2021) Development and evaluation of [125I] IPPI for Tau imaging in postmortem human Alzheimer's disease brain. Synapse 75(1):e22183. https:\/\/doi.org\/10.1002\/syn.22183","journal-title":"Synapse"},{"issue":"5","key":"ref40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature","volume":"71","author":"Nelson PT","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Tredici KD, Duyckaerts C (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathology Experimental Neurol 71(5):362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"3","key":"ref41","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1046\/j.1471-4159.1994.62031062.x","article-title":"Down's syndrome: up-regulation of \u03b2\u2010amyloid protein precursor and \u03c4 mRNAs and their defective coordination","author":"Oyama F","year":"1994","unstructured":"Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y (1994) Down's syndrome: up-regulation of \u03b2\u2010amyloid protein precursor and \u03c4 mRNAs and their defective coordination. J Neurochem 31062\u20131066. https:\/\/doi.org\/10.1046\/j.1471-4159.1994.62031062.x","journal-title":"J Neurochem"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/molecules30050990","article-title":"Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I] Radioiodinated DYRK1A Inhibitor","volume":"30","author":"Paclibar CG","year":"2025","unstructured":"Paclibar CG, Schafer DM, Biju AP, Karim F, Sison SA, Liang C, Ahmed ST, Mukherjee J (2025) Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I] Radioiodinated DYRK1A Inhibitor. Molecules 30(5):990. https:\/\/doi.org\/10.3390\/molecules30050990","journal-title":"Molecules"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13024-019-0312-x","article-title":"Dural lymphatics regulate clearance of extracellular tau from the CNS","volume":"14","author":"Patel TK","year":"2019","unstructured":"Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D (2019) Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol neurodegeneration 14(1):11. https:\/\/doi.org\/10.1186\/s13024-019-0312-x","journal-title":"Mol neurodegeneration"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e092399","DOI":"10.1002\/alz.092399","article-title":"Cortical tau aggregation drives axonal degeneration in white matter fiber tracts in Alzheimer\u2019s disease","volume":"20","author":"Pescoller J","year":"2024","unstructured":"Pescoller J, Dewenter A, Steward A, Dehsarvi A, Wagner F, Gross M, Zhu Z, Ewers M, Roemer SN, Brendel M, Franzmeier N (2024) Cortical tau aggregation drives axonal degeneration in white matter fiber tracts in Alzheimer\u2019s disease. Alzheimer's Dement 20:e092399. https:\/\/doi.org\/10.1002\/alz.092399","journal-title":"Alzheimer's Dement"},{"issue":"10","key":"ref45","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1523\/JNEUROSCI.5561-03.2004","article-title":"Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease","volume":"24","author":"Planel E","year":"2004","unstructured":"Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 24(10):2401\u20132411. https:\/\/doi.org\/10.1523\/JNEUROSCI.5561-03.2004","journal-title":"J Neurosci"},{"issue":"7","key":"ref46","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/dneu.22658","article-title":"Tau PET imaging for staging of Alzheimer's disease in Down syndrome","volume":"79","author":"Rafii MS","year":"2019","unstructured":"Rafii MS (2019) Tau PET imaging for staging of Alzheimer's disease in Down syndrome. Dev Neurobiol 79(7):711\u2013715. https:\/\/doi.org\/10.1002\/dneu.22658","journal-title":"Dev Neurobiol"},{"issue":"9","key":"ref47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1474-4422(25)00237-6","article-title":"Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology","volume":"24","author":"Rafii MS","year":"2025","unstructured":"Rafii MS, Schlachetzki Z, Barroeta I, Head E, Fortea J, Ances BM (2025) Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology. Lancet Neurol 24(9):753\u2013762. https:\/\/doi.org\/10.1016\/S1474-4422(25)00237-6","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13024-023-00645-0","article-title":"Current views on meningeal lymphatics and immunity in aging and Alzheimer\u2019s disease","volume":"18","author":"Rego S","year":"2023","unstructured":"Rego S, Sanchez G, Da Mesquita S (2023) Current views on meningeal lymphatics and immunity in aging and Alzheimer\u2019s disease. Mol neurodegeneration 18(1):55. https:\/\/doi.org\/10.1186\/s13024-023-00645-0","journal-title":"Mol neurodegeneration"},{"issue":"5","key":"ref49","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","article-title":"Dual-specificity tyrosine (Y)\u2010phosphorylation regulated kinase 1A\u2010mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease","volume":"104","author":"Ryoo SR","year":"2008","unstructured":"Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS, Kim MJ, Son MY, Seo H, Chung SH, Song WJ (2008) Dual-specificity tyrosine (Y)\u2010phosphorylation regulated kinase 1A\u2010mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J Neurochem 104(5):1333\u20131344. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05075.x","journal-title":"J Neurochem"},{"issue":"97","key":"ref50","doi-asserted-by":"publisher","first-page":"13122","DOI":"10.1039\/D1CC02327F","article-title":"Increasing membrane permeability of carboxylic acid-containing drugs using synthetic transmembrane anion transporters","volume":"57","author":"Salam R","year":"2021","unstructured":"Salam R, Chowdhury SM, Marshall SR, Gneid H, Busschaert N (2021) Increasing membrane permeability of carboxylic acid-containing drugs using synthetic transmembrane anion transporters. Chem Commun 57(97):13122\u201313125. https:\/\/doi.org\/10.1039\/D1CC02327F","journal-title":"Chem Commun"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias","volume":"12","author":"Sander K","year":"2016","unstructured":"Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD et al (2016) Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias. Alzheimer\u2019s Dement 12:1116\u20131124. https:\/\/doi.org\/10.1016\/j.jalz.2016.01.003","journal-title":"Alzheimer\u2019s Dement"},{"issue":"14","key":"ref52","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.3390\/molecules29143308","article-title":"Radioiodinated tau imaging agent III molecular modeling, synthesis, and evaluation of a new tau imaging agent,[125I] ISAS in post-mortem human Alzheimer\u2019s disease brain","volume":"29","author":"Sison SA","year":"2024","unstructured":"Sison SA, Paclibar CG, Liang C, Mukherjee J (2024) Radioiodinated tau imaging agent III molecular modeling, synthesis, and evaluation of a new tau imaging agent,[125I] ISAS in post-mortem human Alzheimer\u2019s disease brain. Molecules 29(14):3308. https:\/\/doi.org\/10.3390\/molecules29143308","journal-title":"Molecules"},{"issue":"5","key":"ref53","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/jnnp.70.5.624","article-title":"Both total and phosphorylated tau are increased in Alzheimer's disease","volume":"70","author":"Sj\u00f6gren M","year":"2001","unstructured":"Sj\u00f6gren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Gran\u00e9rus AK, Vanderstichele H, Vanmechelen E, Blennow K (2001) Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 70(5):624\u2013630. https:\/\/doi.org\/10.1136\/jnnp.70.5.624","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"ref54","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease","volume":"11","author":"Vogel JW","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, Hansson O (2020) Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease. Nat Commun 11(1):2612. https:\/\/doi.org\/10.1038\/s41467-020-15701-2","journal-title":"Nat Commun"},{"key":"ref55","first-page":"1","article-title":"High yield production of [18F] MK-6240 on the AllinOne synthesizer, a promising PET Tracer for the quantification of Human Neurofibrillary tangles in Alzheimer disease","volume":"61","author":"Vriamont C","year":"2020","unstructured":"Vriamont C, Otabashi M, Warnier C (2020) High yield production of [18F] MK-6240 on the AllinOne synthesizer, a promising PET Tracer for the quantification of Human Neurofibrillary tangles in Alzheimer disease. J Nucl Med 61:1\u20132","journal-title":"J Nucl Med"},{"issue":"10","key":"ref56","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acs.jmedchem.6b00166","article-title":"Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs)","volume":"59","author":"Walji AM","year":"2016","unstructured":"Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Holahan M, O'Malley S, Purcell M, Riffel K, Li J, Balsells J, OBrien JA, Melquist S, Soriano A, Zhang X, Ogawa A, Xu S, Joshi E, Della Rocca J, Hess FJ, Schachter J, Hesk D, Schenk D, Struyk A, Babaoglu K, Lohith TG, Wang Y, Yang K, Fu J, Evelhoch JL, Coleman PJ (2016) Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). J Med Chem 59(10):4778\u20134789. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00166","journal-title":"J Med Chem"},{"issue":"s1","key":"ref57","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.3233\/JAD-2012-129031","article-title":"Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration","volume":"33","author":"Wang JZ","year":"2012","unstructured":"Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K (2012) Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimer\u2019s Disease 33(s1):S123\u2013S139. https:\/\/doi.org\/10.3233\/JAD-2012-129031","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"3","key":"ref58","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1471-4159.1994.62031062.x","article-title":"Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome","volume":"17","author":"Wisniewski KE","year":"1985","unstructured":"Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals Neurology: Official J Am Neurol Association Child Neurol Soc 17(3):278\u2013282. https:\/\/doi.org\/10.1046\/j.1471-4159.1994.62031062.x","journal-title":"Annals Neurology: Official J Am Neurol Association Child Neurol Soc"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease","volume":"9","author":"Xia CF","year":"2013","unstructured":"Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D et al (2013) [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 9:666\u2013676. https:\/\/doi.org\/10.1016\/j.jalz.2012.11.008","journal-title":"Alzheimer\u2019s Dement"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8463304\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8463304\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:06:34Z","timestamp":1767711994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8463304\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":59,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8463304\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,1,6]]},"subtype":"preprint"}}